S&P 500   3,897.80 (+2.27%)
DOW   31,619.08 (+2.22%)
QQQ   321.30 (+2.28%)
AAPL   125.92 (+3.84%)
MSFT   236.57 (+1.80%)
FB   261.51 (+1.51%)
GOOGL   2,060.21 (+1.89%)
TSLA   715.39 (+5.91%)
AMZN   3,121.95 (+0.94%)
NVDA   547.48 (-0.20%)
BABA   239.97 (+0.93%)
CGC   35.09 (+7.15%)
GE   13.18 (+5.10%)
MU   94.11 (+2.82%)
NIO   49.56 (+8.26%)
AMD   85.41 (+1.06%)
T   28.26 (+1.33%)
F   11.98 (+2.39%)
ACB   11.32 (+7.60%)
DIS   195.67 (+3.51%)
BA   224.80 (+6.03%)
NFLX   550.43 (+2.15%)
BAC   35.63 (+2.65%)
S&P 500   3,897.80 (+2.27%)
DOW   31,619.08 (+2.22%)
QQQ   321.30 (+2.28%)
AAPL   125.92 (+3.84%)
MSFT   236.57 (+1.80%)
FB   261.51 (+1.51%)
GOOGL   2,060.21 (+1.89%)
TSLA   715.39 (+5.91%)
AMZN   3,121.95 (+0.94%)
NVDA   547.48 (-0.20%)
BABA   239.97 (+0.93%)
CGC   35.09 (+7.15%)
GE   13.18 (+5.10%)
MU   94.11 (+2.82%)
NIO   49.56 (+8.26%)
AMD   85.41 (+1.06%)
T   28.26 (+1.33%)
F   11.98 (+2.39%)
ACB   11.32 (+7.60%)
DIS   195.67 (+3.51%)
BA   224.80 (+6.03%)
NFLX   550.43 (+2.15%)
BAC   35.63 (+2.65%)
S&P 500   3,897.80 (+2.27%)
DOW   31,619.08 (+2.22%)
QQQ   321.30 (+2.28%)
AAPL   125.92 (+3.84%)
MSFT   236.57 (+1.80%)
FB   261.51 (+1.51%)
GOOGL   2,060.21 (+1.89%)
TSLA   715.39 (+5.91%)
AMZN   3,121.95 (+0.94%)
NVDA   547.48 (-0.20%)
BABA   239.97 (+0.93%)
CGC   35.09 (+7.15%)
GE   13.18 (+5.10%)
MU   94.11 (+2.82%)
NIO   49.56 (+8.26%)
AMD   85.41 (+1.06%)
T   28.26 (+1.33%)
F   11.98 (+2.39%)
ACB   11.32 (+7.60%)
DIS   195.67 (+3.51%)
BA   224.80 (+6.03%)
NFLX   550.43 (+2.15%)
BAC   35.63 (+2.65%)
S&P 500   3,897.80 (+2.27%)
DOW   31,619.08 (+2.22%)
QQQ   321.30 (+2.28%)
AAPL   125.92 (+3.84%)
MSFT   236.57 (+1.80%)
FB   261.51 (+1.51%)
GOOGL   2,060.21 (+1.89%)
TSLA   715.39 (+5.91%)
AMZN   3,121.95 (+0.94%)
NVDA   547.48 (-0.20%)
BABA   239.97 (+0.93%)
CGC   35.09 (+7.15%)
GE   13.18 (+5.10%)
MU   94.11 (+2.82%)
NIO   49.56 (+8.26%)
AMD   85.41 (+1.06%)
T   28.26 (+1.33%)
F   11.98 (+2.39%)
ACB   11.32 (+7.60%)
DIS   195.67 (+3.51%)
BA   224.80 (+6.03%)
NFLX   550.43 (+2.15%)
BAC   35.63 (+2.65%)
Log in
NASDAQ:YMAB

Y-mAbs Therapeutics Stock Forecast, Price & News

$35.32
+0.15 (+0.43 %)
(As of 03/1/2021 11:07 AM ET)
Add
Compare
Today's Range
$35.00
Now: $35.32
$37.05
50-Day Range
$33.68
MA: $45.48
$51.96
52-Week Range
$14.16
Now: $35.32
$55.22
Volume5,166 shs
Average Volume265,839 shs
Market Capitalization$1.43 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.36
Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. The company develops naxitamab that is in Phase 2 clinical trial for the treatment of pediatric patients with relapsed steosarcoma or refractory, and high-risk neuroblastoma, as well as other GD2 positive tumors; and GD2-GD3 Vaccine which is in Phase 2 clinical trial for the treatment of high-risk neuroblastoma. It is developing omburtamab that is in Phase 2 clinical trial for the treatment of desmoplastic small round cell tumors; in Phase 1 clinical trial for the treatment of diffuse intrinsic pontine glioma, as well as for the treatment of pediatric patients with central nervous system and leptomeningeal metastases; The company also engages in the development of huB7-H3 product candidate for the treatment of B7-H3 positive adult solid tumors; and pre clinical development of huCD33 BsAb product candidate for the treatment of huCD33 positive hermatological cancers. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize antibody constructs based on the SADA-BiDE pre-targeted radioimmunotherapy platform. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
Y-mAbs Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:YMAB
CUSIPN/A
CIKN/A
Phone646-885-8505
Employees65
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.01 per share

Profitability

Net Income$-81,030,000.00

Miscellaneous

Market Cap$1.43 billion
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

1.61 out of 5 stars

Medical Sector

325th out of 1,962 stocks

Pharmaceutical Preparations Industry

157th out of 772 stocks

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$35.32
+0.15 (+0.43 %)
(As of 03/1/2021 11:07 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive YMAB News and Ratings via Email

Sign-up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Y-mAbs Therapeutics (NASDAQ:YMAB) Frequently Asked Questions

Is Y-mAbs Therapeutics a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Y-mAbs Therapeutics stock.
View analyst ratings for Y-mAbs Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Y-mAbs Therapeutics?

Wall Street analysts have given Y-mAbs Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Y-mAbs Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Y-mAbs Therapeutics?

Y-mAbs Therapeutics saw a decline in short interest in February. As of February 12th, there was short interest totaling 2,230,000 shares, a decline of 24.1% from the January 28th total of 2,940,000 shares. Based on an average trading volume of 251,700 shares, the days-to-cover ratio is presently 8.9 days. Approximately 8.3% of the company's stock are sold short.
View Y-mAbs Therapeutics' Short Interest
.

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) released its earnings results on Friday, February, 26th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.36.
View Y-mAbs Therapeutics' earnings history
.

How has Y-mAbs Therapeutics' stock been impacted by Coronavirus?

Y-mAbs Therapeutics' stock was trading at $22.98 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, YMAB stock has increased by 56.4% and is now trading at $35.95.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for YMAB?

8 brokerages have issued 1 year target prices for Y-mAbs Therapeutics' shares. Their forecasts range from $45.00 to $71.00. On average, they anticipate Y-mAbs Therapeutics' stock price to reach $59.17 in the next year. This suggests a possible upside of 64.6% from the stock's current price.
View analysts' price targets for Y-mAbs Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Y-mAbs Therapeutics' key executives?

Y-mAbs Therapeutics' management team includes the following people:
  • Mr. Thomas Gad, Founder, Chairman, Pres & Head of Bus. Devel. and Strategy (Age 51, Pay $766.75k)
  • Dr. Claus Juan Møller San Pedro M.D., Ph.D., CEO & Director (Age 59, Pay $967.5k)
  • Mr. Bo Kruse, Exec. VP, Sec., Treasurer & CFO (Age 49, Pay $608.35k)
  • Mr. Joris Wiel Jan Wilms, Sr. VP & COO (Age 47)
  • Dr. Torben Lund-Hansen, Sr. VP & Head of Technical Operations (Age 70)
  • Dr. Steen Lisby M.D., M.Sc., Sr. VP & Chief Scientific Officer (Age 57)
  • Mr. Philip Herman, Sr. VP & Chief Commercial Officer (Age 42)
  • Dr. Vignesh Rajah, Sr. VP & Chief Medical Officer

Who are some of Y-mAbs Therapeutics' key competitors?

What other stocks do shareholders of Y-mAbs Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).

When did Y-mAbs Therapeutics IPO?

(YMAB) raised $80 million in an initial public offering (IPO) on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

What is Y-mAbs Therapeutics' stock symbol?

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.97%), Artisan Partners Limited Partnership (2.59%), Alliancebernstein L.P. (2.49%), Northern Trust Corp (0.87%), Ashford Capital Management Inc. (0.54%) and New York State Common Retirement Fund (0.49%). Company insiders that own Y-mAbs Therapeutics stock include Bo Kruse, David N Gill, James Healy, Johan Wedell-Wedellsborg, Mahiuddin Ahmed, Pedro Claus Juan Moller-San, Thomas Gad and Vignesh Rajah.
View institutional ownership trends for Y-mAbs Therapeutics
.

Which major investors are selling Y-mAbs Therapeutics stock?

YMAB stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Barclays PLC, Aviva PLC, Northern Trust Corp, SG Americas Securities LLC, State of Wisconsin Investment Board, Candriam Luxembourg S.C.A., and Credit Suisse AG. Company insiders that have sold Y-mAbs Therapeutics company stock in the last year include Bo Kruse, David N Gill, Mahiuddin Ahmed, Pedro Claus Juan Moller-San, and Thomas Gad.
View insider buying and selling activity for Y-mAbs Therapeutics
or view top insider-selling stocks.

Which major investors are buying Y-mAbs Therapeutics stock?

YMAB stock was bought by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Ashford Capital Management Inc., BlackRock Inc., Morgan Stanley, Alliancebernstein L.P., New York State Common Retirement Fund, Brookfield Asset Management Inc., and DNB Asset Management AS. Company insiders that have bought Y-mAbs Therapeutics stock in the last two years include James Healy, Pedro Claus Juan Moller-San, and Vignesh Rajah.
View insider buying and selling activity for Y-mAbs Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Y-mAbs Therapeutics' stock price today?

One share of YMAB stock can currently be purchased for approximately $35.95.

How much money does Y-mAbs Therapeutics make?

Y-mAbs Therapeutics has a market capitalization of $1.46 billion. The company earns $-81,030,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis.

How many employees does Y-mAbs Therapeutics have?

Y-mAbs Therapeutics employs 65 workers across the globe.

What is Y-mAbs Therapeutics' official website?

The official website for Y-mAbs Therapeutics is www.ymabs.com.

Where are Y-mAbs Therapeutics' headquarters?

Y-mAbs Therapeutics is headquartered at 230 Park Avenue Suite 3350, NEW YORK NY, 10169.

How can I contact Y-mAbs Therapeutics?

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at 646-885-8505 or via email at [email protected]


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.